Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
Investigators from the pharma concluded that most liquid biopsy false positives and negatives could be traced to technical specifics of individual tests.
Funds raised will help accelerate commercialization of the firm's InVisionFirst-Lung liquid biopsy test and support development of the firm's platform for new indications
The firms plan to use Natera's cell-free DNA liquid biopsy assay to monitor patients' response to Amal's cancer vaccine in combination with immunotherapy.
The company, which previously focused on the development of multiplex PCR assays, is hoping to make its ATOM-seq technology available for research use later this year.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
